

PRESS RELEASE

AFYX Therapeutics A/S completes financing round of DKK 13,7M

Hørsholm, Denmark, April 15th, 2024

After our recent Annual General Meeting the BOD has now in cooperation with the CEO completed an internal financing round to secure the financial basis for the transformation of our company to become an international growth and development biopharmaceutical organization based on the merging of Inphena A/S, Lionheart ApS and Afyx Therapeutics A/S. This new organization is now operating under the name AFYX Therapeutics A/S.

It is the company's intention to continue developing our sales in Denmark and Norway and to plan for an optimal launch of our new product Gefena in 2025 in markets both inside and outside EU – while we also continue establishing daughter companies in other European territories as well as pushing forward the development of our other products.

Within this frame we plan to further expand both our development and commercial organization to secure resources that supports the above.

Financing the expansion of the company, launch of our new products in new markets as well as development activities has required additional funding already in the first half of 2024 and we therefore closed

this first internal round of financing among existing investors in April 2024. In 2025 we plan to raise additional capital to help further financing of our development programs and commercial build out of our products.

The BOD believes that the company in its new shape and form is on track for continued growth and development and the Executive management and BOD are looking forward to driving the new entity created by the merger of the three organizations towards significant international success.

About AFYX Therapeutics A/S – Our company is a **niche biopharmaceutical** company with focus on reformulation and repurposing of pharmaceuticals.

Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and has secured successful IPOs of 3 other companies in the BioPharma Industry (OXiGENE, Inc., Genmab A/S and Y-mAbs Therapeutics, Inc)

Our focus is:

- OBSTETRICS
- NICHE ONCOLOGY
- PAIN AND ADDICTION

CLAUS J. MØLLER-SAN PEDRO

CEO & Founder

**WE IMPORVE PEOPLE'S LIVES BY
TRANSFORMING TOMORROW'S
TREATMENTS!**

